Objectives-Patients with mutations in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene have hypercholesterolemia and are at high risk of adverse cardiovascular events. We aimed to stably express the pathological human D374Y gain-of-function mutant form of PCSK9 (PCSK9 DY ) in adult wild-type mice to generate a hyperlipidemic and proatherogenic animal model, achieved with a single systemic injection with adeno-associated virus (AAV). Approach and Results-We constructed an AAV-based vector to support targeted transfer of the PCSK9 DY gene to liver.
C ardiovascular complications derived from progressive degeneration of the vascular system are expected to remain leading causes of morbidity and mortality worldwide. 1 Hypercholesterolemia and associated atherosclerosis develop through interaction of complex genetic networks with environmental cues. Animal models of atherosclerosis have greatly increased our understanding of the disease and have been instrumental in the development of treatment approaches, with the apolipoprotein-E-deficient (ApoE −/− ) mouse being the most widely used mouse model of atherosclerosis to date. 2 The ApoE protein is synthetized in liver and macrophages and plays an important role in lipid homeostasis. 3, 4 As a component of plasma lipoproteins, it serves as a ligand for cell-surface receptors, such as low-density lipoprotein (LDL) receptor (LDLR) and related proteins. This interaction promotes the cellular uptake of atherogenic particles from the circulation. 5 Homozygous gene deletion of ApoE or Ldlr causes severe hypercholesterolemia and spontaneous atherosclerosis. 6, 7 Another key regulator of lipid homeostasis is proprotein convertase subtilisin/kexin type 9 (PCSK9). Recent animal studies show that PCSK9 reduces hepatic uptake of LDL by increasing the endosomal and lysosomal degradation of LDLR, 8 suggesting a possible treatment target for the nonresponsiveness of a subset of patients treated with cholesterol-lowering statins, who maintain excessive levels of cholesterol, particularly LDL. [9] [10] [11] Mice deficient for PCSK9 protein have low plasma LDL cholesterol levels and are protected against atherosclerosis development 12 ; in contrast, gain-of-function PCSK9 mutants 13 have hypercholesterolemia and accelerated atherosclerosis generation. [14] [15] [16] The most severe mutation described in PCSK9, identified in 2 populations, 10, 17 results in cholesterol levels above 500 mg/dL. The mutation, an amino-acid substitution of Asp374 by Tyr (D374Y), increases the affinity of PCSK9 for the LDLR by ≥10-fold. 18 Further animal research is needed to increase understanding of the biology of PCSK9 in different scenarios, genetic backgrounds. and in association with lipid-altering genetic modifications. More versatile models would help to characterize the effect of different therapies targeting PCSK9.
Adeno-associated virus (AAV) vectors efficiently transduce dividing and nondividing cells, escape immune surveillance, and achieve long-term gene transfer. 19, 20 These features make AAV vectors a successful gene therapy approach for reverting genetic dysfunctions in preclinical models, 21, 22 and to date, these vectors have been tested as a tool for reverting genetic disease. However, the same rationale could be used to cause a disease, generating a model for experimental analysis, but to our knowledge, this alternative application has not been tested to date. Here, we present a method for generating a mouse model of disease by AAV injection and subsequent stable expression of a disease-causing mutation in wild-type mice, demonstrating that AAV-mediated PCSK9 gene transfer induces hyperlipidemia and subsequent atherosclerosis. This method provides a convenient system for exploring potential genetic interactions of PCSK9 and its contribution to atherosclerosis development.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Generation and Long-Term Lipid Profile of AAV-PCSK9 DY Expressing Mice
The liver is the main site of lipoprotein transit and metabolism. Hepatocytes control blood LDL levels through the expression of PCSK9, the major regulator of the LDLR. 23, 24 Dysregulation of this pathway by gain-of-function mutations in PCSK9, such as D374Y 25, 26 (PCSK9 DY ) , is linked to hypercholesterolemia and atherosclerosis. [27] [28] [29] To test the effect of stable liver transexpression of this mutant on plasma lipoprotein homeostasis and atherosclerosis development in adult animals, we generated an AAV vector encoding human PCSK9 DY ( Figure 1A ). PCSK9 DY gene expression was directed to hepatocytes by driving the open reading frame from the liver-specific promoter HCR-hAAH. 30 The AAV-PCSK9 DY vector was used to encapsidate viral particles in serotype 9. A single intravenous femoral injection of 30-day-old wild-type C57BL/6J mice with 3.5×10 10 the liver, measured after 110 days ( Figure 1B ). PCSK9 DY protein release to the bloodstream remained constant during the course of the experiment ( Figure 1C ). PCSK9 DY protein also accumulated in liver samples ( Figure 1D ), demonstrating that this approach is a robust and reproducible method for overexpressing human PCSK9 DY . AAV viral infection does not elicit any reported adverse responses in animals, and postinjection levels of serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase were similar to those of uninfected mice and mice infected with AAV9 viral particles expressing Luciferase (AAV-Luc) from a nonspecific liver promoter ( Figure 1E ). AAV viral infection and ectopic specific-liver expression thus does not induce hepatotoxicity in PCSK9 DY -expressing animals. Consistent with these results, we did not observe changes in white cell counts 2 weeks after infection ( Table I in the online-only Data Supplement), indicating that the viral transduction and extracellular transgene expression did not elicit an immunologic response in these mice. PCSK9 DY transexpression in hepatocytes increased serum cholesterol levels in overnight-fasted mice maintained on a regular chow diet at all postinjection times analyzed ( Figure 2A and 2B). At 30 days post injection, total serum cholesterol (tChol) in AAV-PCSK9 DY transexpressing mice was double that in AAV-Luc-injected controls (307±12 versus 130±24 mg/dL). These differences were moreover maintained 1 year after injection, demonstrating the chronic effect of a single AAV injection on systemic lipid levels. Among cholesterol fractions, LDL levels increased significantly between days 30 and 100 after PCSK9 DY gene transfer (56±4.5 versus 110±6.7 mg/dL; P<0.001) and then remained stable between days 140 and 260 (114.6±8.1 and 127.6±4.6 mg/dL; Figure 2B ). After 1 year, serum LDL in AAV-PCSK9 DY -injected animals fed a regular chow diet was 10-fold higher than in AAV-Luc-injected controls. The AAV PCSK9 gain-of-function approach thus induces a dyslipidemia with a strong LDL component that is sustained over long periods.
To confirm the increase in LDL, we analyzed cholesterol and triglyceride distribution in serum samples by fast protein liquid chromatography. The increases in tChol and triglyceride in PCSK9 DY -expressing C57BL/6J mice were because of specific accumulation of LDL and intermediate density lipoprotein (IDL), suggesting that The in vitro binding affinity of mutant PCSK9 DY to the LDLR is >10× higher than that of wild-type PCSK9. We therefore evaluated whether AAV particles expressing wild-type PCSK9 were able to dysregulate LDL in vivo to a similar or lesser extent as PCSK9 DY . We observed that AAV-PCSK9-infected C57BL/6J mice had significantly lower levels of IDL/LDL lipoproteins in serum samples than AAV-PCSK9 DY -injected mice ( Figure III in the online-only Data Supplement). This difference could explain why individuals expressing PCSK9 DY at similar levels to wildtype PCSK9 can develop severe dyslipidemia.
We also studied the effect of PCSK9 DY expression on the endogenous mRNA and protein levels of PCSK9. Although we did not detect significant differences at the transcriptional level, we observed a consistent accumulation of endogenous mouse PCSK9 in serum samples of mice infected with AAV-PCSK9 DY ( Figure IV in the online-only Data Supplement). This result indicates that when the PCSK9 DY is present, the rate of endogenous mouse PCSK9 protein turnover is slower than normal.
High-Fat-Diet Exacerbates Hyperlipidemia in PCSK9 DY -Expressing Animals
To evaluate the response to fat intake and atherogenesis susceptibility in PCSK9 DY -expressing animals, we tested the effect of high-fat-diet (HFD) on cholesterol management. Mice were injected with AAV-PCSK9 DY or AAV-Luc 60 days before starting the dietary regime. At that time, mice were randomized to the HFD or standard chow for an additional 84 days. Fourteen days after HFD initiation, serum tChol in HFD-fed AAV-PCSK9 DY -transexpressing mice was almost 3× higher than in similarly injected mice fed the chow diet (1165±61 versus 316±21 mg/dL; Figure 3A ). Fast protein liquid chromatography revealed that the hyperlipidemic response to HFD was stronger in the very-low-density lipoprotein (VLDL) and chylomicron (CM) fractions than in the IDL/LDL fraction ( Figure 3B ). In contrast, diet had little significant effect on the cholesterol profile in AAV-Luc-infected mice, demonstrating that the diet-induced hyperlipidemia in AAV-PCSK9 DY -infected mice is a consequence of PCSK9 DY expression ( Figure 3A and 3B ). It is also notable that AAV-Luc and AAV-PCSK9 DY mice maintained a baseline difference in serum tChol and LDL 60 days after virus injection, corresponding to day 0 of the dietary regime (168±2 versus 454±28 mg/dL for tChol, 3A); this difference strengthens the results shown in Figure 2 . We also confirmed that expression of the PCSK9 DY transgene was not suppressed in response to 84 days of HFD ( Figure V in the online-only Data Supplement), consistent with results obtained in the PCSK9 DY transgenic pig model. 28 These data demonstrate that AAV-mediated PCSK9 DY transexpression is a robust and easy methodology for generating animals that develop hyperlipidemia in response to HFD.
Hyperlipidemia can provoke the development of lesions throughout the vasculature, and this is greatly exacerbated by HFD. [5] [6] [7] 26 En face staining of aortas with Oil Red O revealed lesions in the thoracic aortas, aortic arches, and secondary arterial branches of all HFD-fed AAV-PCSK9 DY -transduced mice but not in the vessels of similarly fed AAV-Luc mice ( Figure  VI in the online-only Data Supplement). These results confirm that hyperlipidemia induced by AAV-PCSK9 DY transduction is a useful tool for studies of atherosclerosis. Histological analysis at the aortic sinus also revealed that lesions in fat-fed AAV-PCSK9 DY mice were complex, progressing well beyond the fatty streaks seen in chow-diet-fed mice expressing the PCSK9 DY gene (Figure 4A and 4B) . Immunofluorescence staining for markers of macrophages (F4/80) and smooth muscle (α-smooth-muscle-actin) confirmed macrophage infiltration of the plaque and the migration of smooth muscle cells from the intima to the aortic lumen to form a fibrous cap, features of a developed plaque ( Figure 4C ).
AAV-Mediated PCSK9 DY Expression Induces Hyperlipidemia and Atherosclerosis in Different Genetic Backgrounds
To test the potential of AAV-PCSK9 DY for generating hyperlipidemic animals with different genetic backgrounds, we compared the responses of C57BL/6J, 129/SvPasCrlf, and FVB/NCrl mice. A single intravenous injection of 3.5×10 10 AAV-PCSK9 DY virus altered cholesterol homeostasis in all 3 lineages as measured at 30 days post-AAV injection. Liver PCSK9 DY transexpression led to significant increases in tChol (68%, 36%, and 40%, respectively) with concomitant increases in LDL (152%, 70%, and 138%). Changes in cholesterol fractions remained stable for 60 days (Table) , when the mice were randomized for feeding with HFD or standard chow. All 3 mouse strains showed an HFD-dependent increase in serum lipoprotein levels (Table) .
After killing, mice were analyzed for fast protein liquid chromatography lipid profile ( Figure VII by Masson's tricrome and Oil Red O-staining ( Figure 5A and 5B). Quantification of the cross-sectional area of plaques at the level of the aortic sinus confirmed larger plaques in the atherosclerosis-susceptible C57BL/6J strain than in 129/ SvPasCrlf mice (0.112±0.027 versus 0.007±0.003 mm 2 ) and FVB/NCrl mice, where lesions and foam cells were almost absent ( Figure 5C and Ref. 31 ). Chow-fed AAV-PCSK9 DY C57BL/6J mice did not show the notable basal lesion development seen in HFD-fed mice. Although the overall pattern of lipoprotein changes was seen across all 3 mouse strains, with a diet-induced increase in the IDL/ LDL fraction, there were differences suggestive of differing susceptibility to atherosclerosis, consistent with the reported influence of genetic background on atherosclerosis in ApoE −/− . 32, 33 
Atherosclerotic Lesion Development in ApoE −/− and PCSK9 DY -Expressing Mice
PCSK9 induces posttranslational downregulation of hepatic LDLR by diverting recycling LDLR into the endosomal-lysosomal pathway, leading to degradation. 8, 24 The hypercholesterolemic phenotype of transgenic mice overexpressing wild-type 34 or mutant PCSK9 26 therefore resembles that of LDLR −/− mice. We therefore hypothesized that AAV-PCSK9 DY transduction in an ApoE −/− background would partially recapitulate features of the ApoE −/− LDLR −/− double knockout 5 and ApoE −/− PCSK9 transgenic 12 mice. We first compared serum lipoprotein levels in fasted ApoE −/− mice transduced with AAV-Luc or AAV-PCSK9 DY and maintained on a chow diet ( Figure 6A and 6B) . Consistent with previous findings in ApoE −/− PCSK9 transgenic mice, 12 at 120 days postinjection, lipoprotein levels in AAV-PCSK9 DYtransduced ApoE −/− mice did not differ significantly from the levels in the ApoE −/− AAV-Luc controls fed the same diet ( Figure 6A ). In both AAV groups, lipoprotein levels increased markedly in response to HFD. Over the 84-day dietary regime, ApoE −/− AAV-PCSK9 DY showed higher lipoprotein levels than ApoE −/− AAV-Luc mice, but the difference was statistically significant only at 14 days (743±32 versus 1074±89 mg/dL for tChol). Fast protein liquid chromatography lipoprotein analysis showed that AAV-Luc and AAV-PCSK9 DY mice on an ApoE −/− genetic background and maintained on a chow diet accumulated mainly VLDL/CM lipoproteins. This analysis also confirmed that mice transduced with AAV-PCSK9 DY accumulated more IDL/LDL lipoproteins and that the hyperlipidemic response to HFD was stronger in the VLDL/CM fractions than in the IDL/ LDL fraction ( Figure 6B ).
We then compared plaque size in C57BL/6J and ApoE −/− mice injected with AAV-Luc or AAV-PCSK9 DY particles ( Figure 7A) . ApoE-deficient mice on a chow diet spontaneously develop atheroma plaques at a young age, 6 whereas appearance of lesions in LDLR-deficient or PCSK9transgenic mice requires a longer period or HFD. 12, 35 Quantification of plaque cross-sectional area in slices at the level of the aortic sinus ( Figure 7B AAV-PCSK9 DY -transduced ApoE −/− mice at least double the size of those in single mutants on the same diet ( Figure 7B ), without significantly altering serum cholesterol levels ( Figure 6 ).
Discussion
Our data demonstrate that AAV-mediated long-term gain-offunction of human PCSK9 in mice provides a versatile model of dyslipidemia and atherosclerosis, established with a single intravenous injection. Recombinant AAV vectors support long-term transgene expression in many animal models 22, 36, 37 and humans. 20 Highly attractive features of AAV vectors include their tropism for postmitotic as well as mitotic cells, their intracellular genetic stabilization as predominantly nonintegrated DNA, and their low immunogenicity. 38 One major advantage of AAV-mediated transexpression is its robust stability after a single administration. The clear association between hyperlipidemia and atherosclerotic lesion development in the AAV-PCSK9 DY model could be easily used to test genetic interactions in combination with new transgenic or knockout models without the need for tedious, costly, and time-consuming backcrosses, as we have demonstrated here with the ApoE −/− mice. PCSK9 binds to the low-density lipid receptor family members LDLR, VLDLR, and apolipoprotein receptor-2 (ApoER2) 39 and targets them for degradation. 40 It is possible that the increase in VLDL/CM fractions observed in AAV-PCSK9 DY -infected mice when fed the HFD, together with the minor change in the IDL/LDL fractions, could be mediated by these last 2 receptors. Furthermore, VLDLR knockout mice have normal plasma lipoprotein levels when fed a chow diet. 41 However, in HFD, these mice show a slight increase in circulating triglyceride, 42, 43 similar to what is observed in HFD-fed PCSK9 DY -transduced mice.
The hypercholesterolemia model presented here is based on the expression of a pathological variant of human PCSK9 in wild-type animals. Expression of PCSK9 DY induced the accumulation of endogenous PCSK9 protein without any evident change in mRNA levels. We propose that this alteration might be induced by the sequestration of LDLR by mutant PCSK9 DY , rendering it unable to interact with mouse PCSK9. The endogenous PCSK9 would therefore not be recycled and degraded, increasing its total serum levels ( Figure IV and presented extensive lesions only when fed the HFD. In ApoE −/− mice fed a regular chow diet, AAV-PCSK9 DY transduction has a marginal effect on serum lipoprotein levels, despite the doubling of plaque size compared with single ApoE mutants. A similar doubling of plaque size is seen in AAV-PCSK9 DY -injected ApoE −/− mice fed the HFD. Our data suggest that ApoE is a key factor in atheroma plaque development and clearly uncouples lipid cholesterol levels from plaque size measured at the aortic root.
Our long-term results demonstrate induction of persistent hyperlipidemia over 1 year follow-up. AAV-mediated liver-specific PCSK9 DY transfer induced hyperlipidemia in 100% of injected animals, with no hepatotoxicity or signs of inflammatory response activation. These data are consistent with several ongoing or completed phase I/II clinical trials that show an absence of adverse hepatic events. 20, 44 These data suggest that the AAV-PCSK9 DY transfer strategy is a robust approach for inducing stable liver-specific expression.
Because the link between gain-of-function mutations in PCSK9 and autosomal dominant hypercholesterolemia was made 10 years ago, drug-development strategies for hypercholesterolemia have targeted PCSK9. 45 These strategies involve either reducing PCSK9 production or blocking circulating PCSK9 with neutralizing antibodies. [46] [47] [48] [49] A major advantage of our AAV-injection model is that it is easily applicable in any genetic background in a costeffective manner. This feature makes this system an ideal inhibitor test platform for PCSK9 in multiple genetic contexts.
In summary, we think that AAV transfer methodology has the potential to make valuable contributions to the specific understanding of hyperlipidemia and atherosclerosis and to disease modeling in general. The ability to transexpress human disease-causing mutated genes in a tissue-specific manner in wild-type mice obviates the need for complex backcrosses, nonphysiological gene mutations, and the maintenance of large colonies of genetically modified animals. Moreover, the requirement for small numbers of readily available wild-type animals fits with public concerns and the minimal-use concept expressed in the 3 Rs (3Rs) principle for the rational use of animals in research: Replacement, referring to the use of nonanimal methods; Reduction, referring to the use of fewer animals to obtain comparable information; and Refinement, referring to methods that alleviate or minimize potential suffering or distress. We further envision that the AAV-based approach for gene transfer described here is suitable for general use in studies for which expression of any given gain-of-function transgene induces a disease phenotype and is especially applicable to the generation of disease models in larger animals. Hypercholesterolemia and associated atherosclerosis are leading causes of morbidity and mortality worldwide. Animal models of atherosclerosis are essential investigative tools for expanding our understanding of the disease; however, the generation and maintenance of genetically modified mouse colonies for research is costly. We have developed an alternative method that uses adeno-associated virus vectors, widely used for gene therapy approaches, to express the disease-causing dominant-negative PCSK9 DY mutant to generate a model of hyperlipidemia and atherosclerosis in wild-type mice. Single systemic injection of AAV-PCSK9 DY virus is more versatile, cost-effective, simpler, and time-efficient than transgenic approaches for generating hypercholesterolemic animals. These data suggest AAV-PCSK9 DY -transformed mice could become an advantageous platform for testing specific PCSK9-targeted therapies and demonstrate that adeno-associated virustransfer methodology has the potential to make valuable contributions to the specific understanding of hyperlipidemia and atherosclerosis and to disease modeling in general.
Significance
